ChinaBio Today -- GlaxoSmithKline will begin manufacturing its treatment for flu,
Relenza, in China to supply Chinaâs domestic market. GSK received approval of the drug in September from the SFDA.
Relenza, like Tamiflu from Roche, aims at reducing both ...
[BioSpace - 2 hours ago]